NCI's Advanced Technology Center (ATC), established for the implementation of novel technologies to address biological, clinical, and genetic questions pertinent to human cancers, includes the NCI Core Genotyping Facility, which is overseen by DCEG. The LTG is adjacent to the CGF and consists of three principal investigators and their respective laboratories, which work closely with the expertise in the CGF and DCEG.
The aim of the CGF is to meet the genotyping and selected DNA sequencing needs of the DCEG and NCI's Center for Cancer Research. The facility performs high-throughput genotyping and sequencing to support genetic analysis for a broad range of projects for the intramural research program of the NCI. Working in concert with epidemiologists, biostatisticians and basic research scientists in the intramural research program, the CGF has developed the capacity to conduct genome-wide association studies and candidate gene approaches to identify the heritable determinants of various forms of cancer. The Core Genotyping Facility (CGF) offers a wide variety of sample preparation and genotyping operations. All samples received must meet minimum requirements and are taken through the Sample Handling pipeline prior to completing any genotyping. The Sample Handling pipeline includes DNA quantification and genetic fingerprinting. Also offered is current Whole Genome Amplification (WGA) technology designed to increase available DNA from samples with minimal residual DNA. The genotyping platforms cover a wide-range of size and scope. The CGF operates the Illumina BeadLab system which supports Illumina assay technologies including the whole genome genotyping Infinium assays, custom GoldenGate OPA assays, and Custom Infinium (iSelect) assays. The CGF operates next generation sequencing with two 454/Roche instruments with high throughput analytical capacity for targeted regions identified in GWAS and linkage studies. In addition, the CGF offers Affymetrix GeneChip arrays and uniplex TaqMan genotyping. Informatics at the CGF is focused on two main areas: Information Management, the electronic storage and retrieval of data, and Analytics, the employment of the most appropriate statistical methods to effectively and accurately draw conclusions from the data generated by the laboratory.
| Machiela, Mitchell J; Chanock, Stephen J (2017) The ageing genome, clonal mosaicism and chronic disease. Curr Opin Genet Dev 42:8-13 |
| Machiela, Mitchell J; Zhou, Weiyin; Caporaso, Neil et al. (2016) Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls. J Hum Genet 61:411-8 |
| Zanetti, Krista A; Wang, Zhaoming; Aldrich, Melinda et al. (2016) Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population. Lung Cancer 98:33-42 |
| Zhou, Weiyin; Machiela, Mitchell J; Freedman, Neal D et al. (2016) Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nat Genet 48:563-8 |
| Chung, Charles C; Hsing, Ann W; Edward Yeboah et al. (2014) A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestry. Prostate 74:579-89 |
| Machiela, Mitchell J; Chanock, Stephen J (2013) Detectable clonal mosaicism in the human genome. Semin Hematol 50:348-59 |
| Jacobs, Kevin B; Yeager, Meredith; Zhou, Weiyin et al. (2012) Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 44:651-8 |
| Lambrechts, Diether; Truong, Therese; Justenhoven, Christina et al. (2012) 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat 33:1123-32 |
| Wang, Zhaoming; Jacobs, Kevin B; Yeager, Meredith et al. (2011) Improved imputation of common and uncommon SNPs with a new reference set. Nat Genet 44:6-7 |
| Chanock, Stephen J; Hunter, David J (2008) Genomics: when the smoke clears ... Nature 452:537-8 |
